Trials / Completed
CompletedNCT03256942
Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Primary objective: \- To evaluate the sensitivity of the Merz Lip Fullness Assessment Scale (MLFAS). Secondary objectives: * To evaluate the clinical aesthetic improvement outcome in lips appearance four weeks after Etermis 4® injection. * To evaluate safety/tolerability of Etermis 4® treatment in lips.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Etermis 4® | Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin. |
Timeline
- Start date
- 2017-08-16
- Primary completion
- 2017-11-17
- Completion
- 2017-11-17
- First posted
- 2017-08-22
- Last updated
- 2018-05-23
Locations
6 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT03256942. Inclusion in this directory is not an endorsement.